Clinical Trials Logo

Chronic Hepatitis B Virus clinical trials

View clinical trials related to Chronic Hepatitis B Virus.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05313477 Completed - Vitamin D Clinical Trials

The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With TDF

TDF
Start date: May 1, 2022
Phase: Phase 4
Study type: Interventional

Nucleot(s)ide is an antiviral drug that can reduce the number of viruses, reduce the risk of HCC, regress hepatic fibrosis and reduce death from Hepatitis B viral infection. Tenofovir disoproxil fumarate (TDF) is one of nucleotide analogue that is recommended to treated patients with Hepatitis B viral infection. However, long-term TDF therapy may have side effects especially nephrotoxicity and bone toxicity. Previous studies in human immunodeficiency virus (HIV) infected patients who treated with TDF containing regimen antiretroviral therapy, in vitamin D supplement group had a statistic significance of low parathyroid hormone level and better in bone mineral density regardless of initial vitamin D level. Therefore, the main objective of this study is to evaluate the vitamin D and calcium supplement to patients with hepatitis B who have taken TDF, in parathyroid hormone level, bone mineral density, renal function and renal phosphate loss compared to patients who have no vitamin D and calcium supplement.

NCT ID: NCT00975091 Completed - Clinical trials for Chronic Hepatitis B Virus

Continue Entecavir Rollover From China

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine if treatment with entecavir is safe and well tolerated in patients who completed dosing in a previous entecavir study in China, but are requiring further treatment of their chronic hepatitis B virus infection.